The size of the global genome engineering market is estimated to be worth USD 8.29 billion by 2026 from USD 4.19 billion in 2021, growing at a CAGR of 14.61% from 2021 to 2026.
The Genome Engineering market is a rapidly growing global market, which is mainly driven by the need for a solution for the current-day prevalence of unscrutinized diseases. Scientists from the Francis Crick Institute have discovered rules to determine the precision of CRISPR/Cas9 genome editing in human cells. These rules are expected to help improve the safety and efficiency of genome engineering in both clinics and labs.
The global genome editing and engineering market are mainly driven by the ease of the use of CRISPR technology for genome study and modifications, especially for the cell line engineering application. Also, the need for action to be taken against common cancers and infectious diseases is another primary driver to the growth of the global market.
However, the lack of research and development centers across the globe as they are required drags the growth of the global market in the mentioned forecast period. Also, the global concentration of the genome editing/engineering market in regions like North America and Europe reduces the chances of global market expansion into areas like Africa and the Middle East.
Market Size Available
2020 to 2026
2021 to 2026
By Technology, Application, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Market Leaders Profiled
Transposagen Biopharmaceuticals (US), Thermo Fisher Scientific (US), Editas Medicine, Inc. (US), Merck (Germany), Lonza Group (Switzerland), OriGene Technologies (US), Horizon Discovery Group (UK), Intellia Therapeutics, Inc. (US), GenScript (US), Sangamo BioSciences (US), Cellectis S.A. (France), Integrated DNA Technologies (US), Bluebird Bio, Inc. (US), New England Biolabs (US), Editas Medicine (US), Sigma-Aldrich Corporation (US), and CRISPR Therapeutics (Switzerland)
This research report on the Global Genome Engineering Market has been segmented & sub-segmented into the following categories and analyzed market size & forecast for each segment until 2026.
Genome Engineering Market - By Technology:
Among the mentioned technologies, the CRISPR segment is anticipated to account for the largest share of the global market for genome editing. The exceptional growth is attributed to the convenient usage associated with this technology, along with its multiple capabilities.
Genome Engineering Market - By Application:
Of the mentioned applications, the cell line engineering segment is projected to have the largest share in the forecast period and with the fastest growth rate among others. The growth is because industries are focusing on stem cell research as it has shown decent results in the recent past.
Genome Engineering Market - By End User:
The pharmaceutical and biotechnology companies segment is expected to have the highest growth rate in the forecast as mentioned earlier period due to the increase in the prevalent infectious diseases and cancer, which drive the research to prevent and cure these diseases across the world.
Genome Engineering Market - By Region:
Geographically, the North American genome engineering market leads the global genome engineering market by both value and volume, as of 2020. The situation of all the market key players in this region is the main reason for its leading market position. This region is anticipated to have the highest growth rate in the projected forecast period.
The European genome engineering market is expected to stand second in accounting for the majority share in the global market during the forecast period. The presence of a considerable customer base in and around this region is helping in the growth of the Genome Engineering market in Europe. It makes this the fastest growing regional market in the projected forecast period. Also, the technological supremacy of Europe and North America over the rest of the world is the necessary condition that facilitates them to develop in this emerging field, creating an eye-catching performance in the global market.
The Asia Pacific genome engineering market is predicted to be the fastest-growing regional market in the global market during the forecast period. The locational advantages offered this region, such as ease of setup and cheap resources, and a large number of skilled populations is a significant reason for this region’s position in the global market. However, the lack of healthcare-related advancements and research initiatives in this region makes it only the third fastest-growing region
On the other hand, the Middle East & Africa, and Latin America regions, being in the low developing countries due to the contribution of low GDP countries, have fewer opportunities for market growth. Hence, the Genome Engineering Market grows at a slow pace in these regions.
KEY MARKET PLAYERS:
By the end of 2020, Transposagen Biopharmaceuticals (US), Thermo Fisher Scientific (US), Editas Medicine, Inc. (the US), Merck (Germany), Lonza Group (Switzerland), OriGene Technologies (US), Horizon Discovery Group (UK), Intellia Therapeutics, Inc. (US), GenScript (US), Sangamo BioSciences (US), Cellectis S.A. (France), Integrated DNA Technologies (US), Bluebird Bio, Inc. (the US), New England Biolabs (US), Editas Medicine (US), Sigma-Aldrich Corporation (US), and CRISPR Therapeutics (Switzerland) are the leading shareholders of the global market for Genome Engineering. There is constant competition between these companies regarding the pricing and quality of the product. They are currently focused on providing expansion strategies to improve their market value and position.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2.2 Cell Line Engineering
5.2.3 Animal Genetic Engineering
5.2.4 Plant Genetic Engineering
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 End User
5.3.2 Biotechnology & Pharmaceutical Companies
5.3.3 Contract Research Organizations
5.3.4 Academic & Research Institutes
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Technology
22.214.171.124 By Application
126.96.36.199 By End User
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Technology
220.127.116.11 By Application
18.104.22.168 By End User
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Technology
188.8.131.52 By Application
184.108.40.206 By End User
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Transposagen Biopharmaceuticals
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific
8.3 Editas Medicine, Inc.
8.5 Lonza Group
8.6 OriGene Technologies
8.7 Horizon Discovery Group
8.8 Intellia Therapeutics, Inc.
8.10 Sangamo BioSciences
8.11 Cellectis S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures